Sirion Biotech GmbH: Viral vectors for novel cell models, gene therapy and vaccine development gain further funds from private investors
(firmenpresse) - (DGAP-Media / 09.04.2013 / 09:04)
SIRION Biotech GmbH closes new financing round with additional investors
Munich, Germany, SIRION Biotech GmbH has won two additional private
investors, one of them being Aumenta GmbH. Both contribute to a large
extent to the current financing round side by side with the existing
investors Creathor Venture, HTGF, Bayernkapital and KfW, next to the
Managing Directors. The new funds will further strengthen access to the
Japan and USA markets and drive the evaluation of clinical programs for
viral vectors and commercial projects for novel cell models. The
laboratories in Munich will be expanded by GLP facilities (Good Laboratory
Practice).
In its 6th year, the company has accelerated its growth dynamics with over
100 clients conducting discovery and research in industry and academia: all
signs point to a high time for working with strategic cell models, close to
reality. In addition, viral vectors are increasingly being used for novel
vaccines and gene therapies. The first gene therapy application has
recently been approved in Europe last November. One of SIRION's core
competences is the design of de novo viral vectors and subsequently of
custom cell models. The company has also developed Ad19a, a novel vector
envelope, that shows superior performance in animal and human organisms,
transducing cell types that are immunologically relevant.
Stemming from its fee-for-service business the company has experienced a
wide variety of applications in over 300 single projects and accesses a
large science network. Individual leads with high clinical potential will
be pursued in collaborations to which the company contributes its
scientific competence and GLP facility. About half a dozen such
collaborations have already been initiated or are close to being executed.
On SIRION Biotech:
SIRION Biotech was founded in Munich in 2006 with the idea of enabling
novel cell models closer to reality than ever before. This required the
assembly of an all-encompassing, novel viral vector platform. Both,
designing de novo viral vectors and the subsequent creation of custom cell
models will pave the way for superior compound development in the drug,
cosmetics and food industries. SIRION's technologies have been validated in
over 300 single projects with more than 100 academic and industrial
partners. As a result, primary cell immortalizations have become highly
reliable, as have de novo viral vectors to be used in gene therapy and
vaccine applications.
Kontakt:
SIRION BIOTECH GmbH
Dr. Christian Thirion
Am Klopferspitz 19
D-82152 Martinsried
Tel.: +49-89-700 961 99-15
eMail: Thirion(at)Sirion-Biotech.com
www.SIRION-Biotech.com
End of Media Release
---------------------------------------------------------------------
Issuer: Sirion Biotech GmbH
Key word(s): Enterprise
09.04.2013 Dissemination of a Press Release, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
206288 09.04.2013
Themen in dieser Pressemitteilung:
sirion-biotech-gmbh-viral-vectors-for-novel-cell-models
gene-therapy-and-vaccine-development-gain-further-funds-from-private-investors
Unternehmensinformation / Kurzprofil:
Datum: 09.04.2013 - 09:04 Uhr
Sprache: Deutsch
News-ID 247005
Anzahl Zeichen: 6247
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 337 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sirion Biotech GmbH: Viral vectors for novel cell models, gene therapy and vaccine development gain further funds from private investors"
steht unter der journalistisch-redaktionellen Verantwortung von
Sirion Biotech GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
